https://www.taxtmi.com/caselaws?id=386232 The Tribunal dismissed the Revenue's appeal, upholding the CIT(A)'s order that deleted the addition made by the AO. It was held that the expenditure incurred by the pharmaceutical company for business promotion purposes was allowable under Section 37(1) of the Income Tax Act. The Tribunal clarified that the MCI guidelines did not apply to pharmaceutical companies, and the expenses were not in violation of any law or public policy. The decision was pronounced on 18th September 2019. en-us Wed, 18 Sep 2019 00:00:00 +0530 Wed, 25 Sep 2019 06:40:43 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=386232 The Tribunal dismissed the Revenue's appeal, upholding the CIT(A)'s order that deleted the addition made by the AO. It was held that the expenditure incurred by the pharmaceutical company for business promotion purposes was allowable under Section 37(1) of the Income Tax Act. The Tribunal clarified that the MCI guidelines did not apply to pharmaceutical companies, and the expenses were not in violation of any law or public policy. The decision was pronounced on 18th September 2019. Case-Laws Income Tax Wed, 18 Sep 2019 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=386232